ReviewCurrent cardiology reports2025
Beyond the Heart: Exploring Extracardiac Manifestations in Cardiac Amyloidosis for Early Diagnosis.
Review in Current cardiology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis review examines extracardiac manifestations of cardiac amyloidosis and their potential role in early diagnosis and management. Multisystem involvement, including musculoskeletal, peripheral nervous system, and other extracardiac findings are highlighted to serve as red flags for earlier detection. RECENT
findingsEarly screening for high-risk individuals over 50 with CTS or spinal stenosis could enable earlier intervention. Peripheral neuropathy and CTS often precede cardiac involvement by 5-10 years, while spinal stenosis can precede it by 5-15 years. Other indicators include biceps tendon rupture, trigger finger, and gastrointestinal issues. MRI shows promise in detecting amyloid-related changes, especially wrist MRI. More studies are needed. Recognizing extracardiac findings may enable earlier diagnosis and intervention before significant cardiac dysfunction. Current workflows use extracardiac manifestations to detect cardiac amyloidosis after cardiac involvement. Integrating these insights earlier could identify amyloidosis years before cardiac issues, improving screening, patient outcomes, and guiding future therapies.
Indexed as
Identifiers
40563051What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.